Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Science Board meeting

Executive Summary

FDA's Science Board will wrap up its review of FDA's drug safety programs March 31; during a meeting in November, the agency outlined a restructuring of its drug safety operations (1"The Pink Sheet" Nov. 7, 2005, p. 3). The panel will also discuss a request from FDA to review the agency's science program. The meeting will be held at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m...

You may also be interested in...

FDA’s Drug Center Reorganization Creates Second Safety Director Position

The Center for Drug Evaluation & Research will divide its drug safety functions between a new associate center director and its existing Office of Drug Safety

Woodcock Faces Maze Of Rules To Become Commissioner Nominee

Vacancies Reform Act requires individual in an acting position to step down in order to be nominated to the permanent post but there are exceptions. Andrew von Eschenbach retained acting title during his nomination in 2006.

Even As Acting US FDA Commissioner, Woodcock Still Holds Multiple Positions

To help with the transition to Biden’s COVID-19 response, Woodcock will retain some therapeutic development duties in the program the Trump administration had called Operation Warp Speed.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts